{"name":"Medipost, Inc.","slug":"medipost-inc","ticker":"","exchange":"","domain":"medipost.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CARTISTEM® + Debridement","genericName":"CARTISTEM® + Debridement","slug":"cartistem-debridement","indication":"Articular cartilage defects of the knee (Grade 3-4 chondral lesions)","status":"phase_3"}]}],"pipeline":[{"name":"CARTISTEM® + Debridement","genericName":"CARTISTEM® + Debridement","slug":"cartistem-debridement","phase":"phase_3","mechanism":"CARTISTEM is an allogeneic bone marrow-derived mesenchymal stem cell product that regenerates damaged cartilage tissue when combined with surgical debridement.","indications":["Articular cartilage defects of the knee (Grade 3-4 chondral lesions)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNSzAwaEtVM002N1NxcUVPeEVZdUpDSEhUaDEybkFOR3hQSkpsdzNDdWRqS3lYNUFzZUhFeGFVcE5DQ2RzaDhXd2RVeWVVZm9UbzVIUzZ3QjUyYVl1cDVQRXZXOTlocGM3ZWptYUplUzVENWw1eHhHUG1FSlVsMVF3aHplWXBHMHJhUW9xLV9NN2ZlTTl3d3RBbnVZYWR0QTNrYmZHTXFsZ2NNcWVsSTB2Rm5waTljQ25kUUpWVXFJYUFlSGhhMU0xQmlOcHRWNEtwMzN1LTJmaw?oc=5","date":"2026-02-13","type":"trial","source":"BioSpace","summary":"MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial - BioSpace","headline":"MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBRWnQ2OEUxWDhTcW1rVEtHS0NQbjI1SEdsTUpTU3dJeTNyaFRVTzRGbzhPWXBuYlhmOWQ0Z1NwNWlRSVpTMEJPb3VzVkpwNzROYjc0WEh6aHdJYmVqQ3VIZ3J3TTg2UjFWd0hPY0Rn?oc=5","date":"2026-02-03","type":"pipeline","source":"KED Global","summary":"Korea's Medipost, success story of tech-focused private equity firms Crescendo, Skylake - KED Global","headline":"Korea's Medipost, success story of tech-focused private equity firms Crescendo, Skylake","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPTXRZbDdxR2p1VXFVQTlleGFCcGZ5ZWFJMlRxdmN3Tzl4WlBKYjg3TzU1RE9UZWNEakdTSEVIWl9PcW12dldteTR3eDdPTDc5SFNjbXJLN1plcDBLRVlza2lOREFJMWtZU0lLUEd4N1l3b0VBX3lRNlVlamI0QUhMUU5jVUN6cXc?oc=5","date":"2026-01-09","type":"pipeline","source":"Pharmaceutical Executive","summary":"Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026 - Pharmaceutical Executive","headline":"Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPTDJPaXVCQ1NlaXFXbnR0NURYY0Zrdy11RERQZnhNTTRPeUlVaWZPdUhybWZPempGc1BOV1Jjc3g4Y0NrWV9UR2JkQTRKWHBkamR2RlBoLTZ0d2RvajhrenNKMmI0c21ZNkF0QTBYdjA5SDlUTURpSF9kT3pKclRmeVd2a1FMQ3J5ZHhLclU0dHFuSzViQ0xPaDZSSm41SXI0VjNRS05aaVFGUXgtU1hBSHdhSFdMVXE4RktsaWxMTUE2aHRIdmZJOFhxM3JiRkdaUy11RlMwRF9Ud2hqVGlJaHVLZHBleFk?oc=5","date":"2026-01-09","type":"pipeline","source":"businesswire.com","summary":"MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development - businesswire.com","headline":"MEDIPOST Inc. Announces $140 Million in Funding to Accelerate Late-Stage Clinical Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1yZmFMTGc2RVVfamlaT2RQVm5JbmJOVllTQVRNaXdpZUdUeXJYWXdXbVBUN1ZGS0hjRWxONjRqeWlsQ3ZOMm9LQ2o1Y3U3LXB3SXBZVkxEME5fTElKenBTeDJB?oc=5","date":"2025-12-19","type":"deal","source":"동아비즈니스리뷰 | DBR","summary":"MediPost Secures KRW 205 Billion, Seals KRW 11.8 Billion Japan Deal - 동아비즈니스리뷰 | DBR","headline":"MediPost Secures KRW 205 Billion, Seals KRW 11.8 Billion Japan Deal - 동아비즈니스리뷰 | DBR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPaFp4bXJpcUlOSF9ZMVU1aTEtNi0tMXcwNXM5Y19pNzdGaGIwcHNIM013Yl9XWE1jaFZ5NDZGYXozcFpNbHFwd0N1TGJJWXY1Nm45R2ZQdWhHdGlEZnRMenE4MGplN2NxWFNFQVZUVWNYYkhJSlhOV1hmem1IQVdBcFJDVnBQZVVBMnFSUVBwVi1YSnZ3YWJlMHRsS25TMDlzZzJIV2UyT3dBcVcwY2JXbjkwUnRwXzY4R1ZUZC1LNkQ3OHRyS25fRFg1RlB4OVhHVHB4bzRITDludmhWd1JTTFA3TlJTZmJhR1pZcGJhcnc2WGlZVVZRNWVOTGp4cEFralJWeE91cmVqdkhHSl9R?oc=5","date":"2025-12-19","type":"deal","source":"BioSpace","summary":"MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan - BioSpace","headline":"MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOUlZNcDZjYWxVbTZwRktTWmtnVERhMWFOa2Y1SE4yTVNaUGRwdnN4NDlpdXB3WExWcWhBU1h4ZlRjMUY0UE9NdEJsZUQtUzVzWUV0M29pcTZlb3VLTXdlWi1HQ055b3Rvei1GQmVHS1dXTjJ3a2t4YTNYWl9QcFFWUXB6Ny1BMVAyX2ZXWER3UUtKX3p1akh4bmFhY1R4UEs2UUpNN09SMmhnWjNwRTRleVNfUEdMdUFESW9UbkRGLXBOeURuZm1WQzRlRnNhb2NtRFJXbjkyMlZSSkpTTmt6blQ1X3JxNGRiaGsyVjNvYw?oc=5","date":"2025-04-21","type":"pipeline","source":"CRISPR Medicine News","summary":"Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organ","headline":"Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Blueb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9DNFktajRZUWxIbEZiS1hFMVRrX1JhNkFlYVVGNTlsS0RNVUdYaG85OHRmMXZlaFNZUWFlUjF1SV9hZW5tR3JGSGdPVnBrekhhbXRVTFZxd0VJSTcxUFM2c2tzcElndzNxclNyT2pn?oc=5","date":"2023-02-28","type":"regulatory","source":"KED Global","summary":"S.Korea's Huons gets approval to supply anesthetics to Canada - KED Global","headline":"S.Korea's Huons gets approval to supply anesthetics to Canada","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5UOXluQkN6OHRGaTR2Q1BLVnNwbzBIYXNraUQxb1h0VXEwTGY0ZldZN2taZEdndlZPN1U4blhCYmdfNWd4dXFIaDVIeGExaWFRaHd4Ylc4MzZ5ejNjRGdBS3ctZVZKTDY5cUdoREV3?oc=5","date":"2023-01-17","type":"trial","source":"KED Global","summary":"Medipost completes first dose of Cartistem in phase 3 clinical trials in Japan - KED Global","headline":"Medipost completes first dose of Cartistem in phase 3 clinical trials in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE04VHhvOWI3LTQzQ3ppdVRQZVlrMlJCZ2RWN1kzaDQ0Q0g3SUhBNnYybVRoOE1rdm94dkNGM0pNb3J0enkyRGNjNnRLMW1SVGotd1VneFg3WFlrY2JaeWxsNk92ZUtOb1VoZ1huSDln?oc=5","date":"2022-05-31","type":"deal","source":"KED Global","summary":"Medipost acquires Canada’s OmniaBio for CDMO business - KED Global","headline":"Medipost acquires Canada’s OmniaBio for CDMO business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9jUW1QbTJQQVdIMERzNm55SGdTNWE3Z0ZnOGM0ZU4yRkJ2ekhBUjJPbURNNUFrOUk0d0tsMURwWVJ2ZGRQNnBoS0xEYWlUSll0QUJhbGEycFJDcGttOGNVZUxCUkxCZk5uWUJCMExROTMtQzdX?oc=5","date":"2022-03-17","type":"deal","source":"KED Global","summary":"Private equity consortium buys 30% stake in biotech firm Medipost - KED Global","headline":"Private equity consortium buys 30% stake in biotech firm Medipost","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBtM0o4VzVUTllIbjFGY0Fndm44bnd3YWRvWmN4QmJKWWF2cG5ZSDNGQ0xvTVlsZVZWZDB6YXRKZWsybTFoeE53UXBfRFpVbWlXdDktT0pmWQ?oc=5","date":"2011-04-18","type":"pipeline","source":"The Korea Herald","summary":"[Meet the CEO] Medipost hopes to fuel stem cell renaissance - The Korea Herald","headline":"[Meet the CEO] Medipost hopes to fuel stem cell renaissance","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}